Pipeline: Human Health Initiatives
Hennepin Life Sciences (HLS) has a lead technology that has completed preclinical development and is entering a Phase II clinical trial for the treatment of bacterial vaginosis. HLS also has several antimicrobial technologies that are currently being prepared to enter the clinical phase of development for the treatment of infections in humans including vaginal candidiasis, urinary tract infections and skin and soft tissue infections.| Area of Focus | Infectious Disease | Clinical Product Number | Stage of Development |
|---|---|---|---|
| Women's Health | Bacterial vaginosis and candidiasis | ABV3 | Preclinical complete Clinical Initiating Phase II trial |
| Genitourinary | Urinary Tract Infections | AU1 | Preclinical SBIR awarded to develop technologies to prevent urinary tract infections |
| Dermatological | Skin and Soft Tissue Infections | AH2 | Preclinical |